



Universiteit  
Leiden  
The Netherlands

## **Healthy elderly in clinical trials: how to define preclinical Alzheimer's Disease for clinical trial participation**

Prins, S.

### **Citation**

Prins, S. (2023, April 5). *Healthy elderly in clinical trials: how to define preclinical Alzheimer's Disease for clinical trial participation*.  
Retrieved from <https://hdl.handle.net/1887/3590274>

Version: Publisher's Version

[Licence agreement concerning inclusion of  
doctoral thesis in the Institutional Repository of  
the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3590274>

**Note:** To cite this publication please use the final published version (if applicable).

**HEALTHY ELDERLY IN CLINICAL TRIALS**  
HOW TO DEFINE PRECLINICAL ALZHEIMER'S DISEASE  
FOR CLINICAL TRIAL PARTICIPATION

VOOR MAMA

# **HEALTHY ELDERLY IN CLINICAL TRIALS**

## **HOW TO DEFINE PRECLINICAL ALZHEIMER'S DISEASE FOR CLINICAL TRIAL PARTICIPATION**

### **PROEFSCHRIFT**

Ter verkrijging van de graad van Doctor  
aan de Universiteit Leiden op gezag van  
Rector magnificus prof.dr.ir. H. Bijl  
volgens besluit van het College van Promoties  
te verdedigen op woensdag 5 april 2023  
klokke 10:00 uur

### **DOOR**

Samantha Prins  
Geboren te Hillegom in 1987

**Promotores:**

Prof.dr. G.J. Groeneveld

Prof.dr. J.M.A. van Gerven

**Co-promotor:**

dr. Laura Borghans

**Leden promotiecommissie:**

Prof.dr. Huub Middelkoop

Prof.dr. Charlotte Teunissen (Amsterdam Universitair Medisch Centrum)

Prof.dr. Gerard Jan Blauw

dr Niels Prins (Brain Research Center)

**Photography**

Samantha Prins

**Design**

Caroline de Lint, Den Haag (caro@delint.nl)

The publication of this thesis was financially supported by the foundation Centre for Human Drug Research (**CHDR**) in Leiden, the Netherlands

**CHAPTER I**

- 7 Introduction

**CHAPTER II**

- 29 Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery

**CHAPTER III**

- 49 Utility of animal models to understand human Alzheimer's disease, using the mastermind research approach to avoid unnecessary further sacrifices of animals

**CHAPTER IV**

- 85 A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation

**CHAPTER V**

- 105 The usefulness of plasma amyloid as a prescreener for the earliest Alzheimer pathological changes depends on the study population

**CHAPTER VI**

- 109 Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease

**CHAPTER VII**

- 125 Neurocognitive functions are not impaired in subjects with preclinical AD based on CSF A $\beta$  and higher levels of CSF P-TAU217

**CHAPTER VIII**

- 143 Summary and Discussion  
157 Nederlandse samenvatting  
167 Curriculum Vitae  
169 List of publications